Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Why GenMark Stock Soared Today
09:30pm, Monday, 15'th Mar 2021
A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.
GenMark Shares Surge After Roche Announces $1.8 Billion Deal for Molecular Test Maker
10:21am, Monday, 15'th Mar 2021
Shares of U.S.-based GenMark were shooting higher on Monday, after Swiss pharmaceutical group Roche said it will buy the California-based company.
Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B
10:13am, Monday, 15'th Mar 2021
Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.
Roche to buy U.S. based GenMark Diagnostics for £1.29 billion
06:58am, Monday, 15'th Mar 2021
Roche Holding AG (SWX: RO) said on Monday that it will buy GenMark Diagnostics (NASDAQ: GNMK) for £1.29 billion. The all-cash deal translates to £17.25 per share.
Roche Diagnostics CEO: GenMark deal will further expand global reach
06:29am, Monday, 15'th Mar 2021
Roche Diagnostics CEO Thomas Schinecker discusses the Swiss pharma company's acquisition of GenMark Diagnostics for $1.8 billion.
Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark
03:48am, Monday, 15'th Mar 2021
Swiss drug giant Roche Holding AG (OTC: RHHBY) announced a big-ticket acquisition that would boost its presence in the diagnostics market, setting the tempo for a merger Monday. What Happened: Roche s
Roche agrees to buy GenMark Diagnostics in $1.8 billion deal
02:48am, Monday, 15'th Mar 2021
Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.
Basel, 15 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) today announced that they have entered into a definitive merger agreement for Roche to fully acquire Ge
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
01:17pm, Friday, 12'th Mar 2021
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
Roche's Tocilizumab, Gilead's Remdesivir Combo Fails To Improve Hospital Discharge Time in COVID-19 Study
06:37am, Thursday, 11'th Mar 2021
Roche Holdings AG (OTCQX: RHHBY) has announced data from Phase 3 REMDACTA trial evaluating Actemra/RoActemra (tocilizumab) plus Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir). The
Here's Why Roche Looks Undervalued At $41
06:30am, Thursday, 11'th Mar 2021
Roche's ADR looks attractive at current levels of $41, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a
Roche's awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems
01:03am, Thursday, 11'th Mar 2021
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organizat
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
01:00am, Thursday, 11'th Mar 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global Phase III randomized, double-blind, multicenter REMDA
AbbVie and Roche Will be Hardest Hit by Patent Expirations
04:59pm, Tuesday, 09'th Mar 2021
Top-selling drugs from AbbVie Inc.(NYSE:ABBV) and Roche (RHHBY) head the list of medications that will lose patent protection this year. How the losses affect the companies' bottom lines—and perhaps
FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer
07:22am, Tuesday, 09'th Mar 2021
The FDA has approved Roche Holdings AG's (OTCMKT: RHHBY) Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment w
